Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers.
作者： Nishant Mohan , Jiangsong Jiang , Milos Dokmanovic , Wen Jin Wu
DOI: 10.1093/ABT/TBY003
关键词:
摘要: Trastuzumab, an epidermal growth factor receptor 2 (HER2) targeting humanized monoclonal antibody, has been approved for the treatment HER2-positive breast cancer and HER2-positve metastatic gastric cancer. However, cardiotoxicity associated with its clinical application poses challenges clinicians patients, mechanisms of which are still evolving. This review will summarize current mechanistic understanding trastuzumab-mediated cardiotoxicity, discuss novel role DNA topoisomerase IIB as a shared target enhanced induced by trastuzumab anthracyclines-based combination regimens, speculate potential impact intervention in immune checkpoint inhibitors-based therapies.
oup.com
sci-hub.se 参考文章(35)
Pimprapa Vejpongsa, Edward T.H. Yeh, Prevention of Anthracycline-Induced Cardiotoxicity: Challenges and Opportunities Journal of the American College of Cardiology. ,vol. 64, pp. 938- 945 ,(2014) , 10.1016/J.JACC.2014.06.1167
Milos Dokmanovic, Yun Wu, Yi Shen, Jieqing Chen, Dianne S Hirsch, Wen Jin Wu, Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition Cancer Biology & Therapy. ,vol. 15, pp. 1029- 1041 ,(2014) , 10.4161/CBT.29171
Steven A. Crone, You-Yang Zhao, Lian Fan, Yusu Gu, Susumu Minamisawa, Yang Liu, Kirk L. Peterson, Ju Chen, Ronald Kahn, Gianluigi Condorelli, John Ross Jr, Kenneth R. Chien, Kuo-Fen Lee, ErbB2 is essential in the prevention of dilated cardiomyopathy Nature Medicine. ,vol. 8, pp. 459- 465 ,(2002) , 10.1038/NM0502-459
Merel Gijsen, Peter King, Tim Perera, Peter J. Parker, Adrian L. Harris, Banafshé Larijani, Anthony Kong, Correction: HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer PLOS Biology. ,vol. 14, pp. e1002414- ,(2010) , 10.1371/JOURNAL.PBIO.1002414
M. Khair ElZarrad, Partha Mukhopadhyay, Nishant Mohan, Enkui Hao, Milos Dokmanovic, Dianne S. Hirsch, Yi Shen, Pal Pacher, Wen Jin Wu, Trastuzumab Alters the Expression of Genes Essential for Cardiac Function and Induces Ultrastructural Changes of Cardiomyocytes in Mice PLoS ONE. ,vol. 8, pp. e79543- ,(2013) , 10.1371/JOURNAL.PONE.0079543
Deepa Wadhwa, Nazanin Fallah-Rad, Debjani Grenier, Marianne Krahn, Tielan Fang, Roien Ahmadie, Jonathan R. Walker, Danica Lister, Rakesh C. Arora, Ivan Barac, Andrew Morris, Davinder S. Jassal, Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study Breast Cancer Research and Treatment. ,vol. 117, pp. 357- 364 ,(2009) , 10.1007/S10549-008-0260-6
Neil L. Spector, Kimberly L. Blackwell, Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Journal of Clinical Oncology. ,vol. 27, pp. 5838- 5847 ,(2009) , 10.1200/JCO.2009.22.1507
Dennis Slamon, Wolfgang Eiermann, Nicholas Robert, Tadeusz Pienkowski, Miguel Martin, Michael Press, John Mackey, John Glaspy, Arlene Chan, Marek Pawlicki, Tamas Pinter, Vicente Valero, Mei-Ching Liu, Guido Sauter, Gunter von Minckwitz, Frances Visco, Valerie Bee, Marc Buyse, Belguendouz Bendahmane, Isabelle Tabah-Fisch, Mary-Ann Lindsay, Alessandro Riva, John Crown, None, Adjuvant Trastuzumab in HER2-Positive Breast Cancer The New England Journal of Medicine. ,vol. 365, pp. 1273- 1283 ,(2011) , 10.1056/NEJMOA0910383
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh, Giuseppe Aprile, Evgeny Kulikov, Julie Hill, Michaela Lehle, Josef Rüschoff, Yoon-Koo Kang, None, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial The Lancet. ,vol. 376, pp. 687- 697 ,(2010) , 10.1016/S0140-6736(10)61121-X
Pharmacovigilance Study Team, E. J. A. Bowles, R. Wellman, H. S. Feigelson, A. A. Onitilo, A. N. Freedman, T. Delate, L. A. Allen, L. Nekhlyudov, K. A. B. Goddard, R. L. Davis, L. A. Habel, M. U. Yood, C. Mccarty, D. J. Magid, E. H. Wagner, Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study Journal of the National Cancer Institute. ,vol. 104, pp. 1293- 1305 ,(2012) , 10.1093/JNCI/DJS317